Amerikanische Gesellschaft für Hirudotherapie

Tanzania Medicines and Medical Devices Authority

TMDA · Tanzania · africa

Regulatory jurisdiction profileJurisdictional reference
Unregulatednational regulator

Tanzania's Medicines and Medical Devices Authority — leech-specific regulatory pathway has not been independently verified by ASH; medicinal leeches fall under the general national medical device framework or traditional-medicine pathways as appropriate.

Regulatory Profile

Agency type
national regulator
Region
africa
Country
Tanzania
Leech status
unregulated
Last ASH review
2026-05-26

Relevant Regulation Codes

  • Tanzania Medicines and Medical Devices Act, Cap 219 (Revised Edition)
  • Tanzania Traditional and Alternative Medicines Act, 2002

Prescriber Requirements

  • Medical Council of Tanganyika–registered physician — order required for any biomedical device application
  • Traditional and alternative medicine practitioners registered under the Traditional and Alternative Medicines Council may have separate scope; specific hirudotherapy authorisation not independently verified by ASH

Supply Chain & GMP

TMDA registration as applicable; English and Kiswahili-language labelling. Standard cold-chain conditions.

Import/Export Rules

TMDA import authorisation; Ministry of Livestock and Fisheries / veterinary services clearance for live invertebrates; CITES Appendix II paperwork for Hirudo medicinalis / verbana.

Reimbursement Context

Not covered under public insurance schemes (NHIF) for leech therapy specifically.

ASH Editorial Notes

Leech-specific pathway not independently verified by ASH; falls under general medical device / traditional medicine framework as appropriate. TMDA is a WHO-listed Maturity Level 3 regulator for medicines (East African Community harmonisation); whether this maturity extends to live-organism medical devices has not been independently mapped by ASH.

Related Jurisdictions

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.